Fulcrum Therapeutics, Inc. cash flow to debt ratio of -932.25% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Fulcrum Therapeutics, Inc.'s free cash flow has decreased 2.32K% from $-2.50M last year to $-60.38M, signaling decreasing performance

Fulcrum Therapeutics, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Fulcrum Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.02 today, signaling strengthened financials

Fulcrum Therapeutics, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Fulcrum Therapeutics, Inc.'s latest filing, so interest coverage cannot be calculated.

Fulcrum Therapeutics, Inc.'s profit margin has increased (-100.00%) in the last year from -12.16% to 0.00%, signaling increasing performance

Fulcrum Therapeutics, Inc.'s short-term assets of $357.48M exceed its short-term liabilities of $13.05M

Fulcrum Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Fulcrum Therapeutics, Inc.'s return on equity of -28.54%, is lower than 15.00%, indicating bad performance

Fulcrum Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Fulcrum Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Fulcrum Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Fulcrum Therapeutics, Inc. has negative free cash flow, indicating cash burn

Fulcrum Therapeutics, Inc.'s yearly earnings has decreased 669.97% since last year from $-9.72M to $-74.88M, signaling decreasing performance

Fulcrum Therapeutics, Inc.'s yearly revenue has decreased 100.00% since last year from $80.00M to $0.00, signaling decreasing performance

ROIC -27.40% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Fulcrum Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Fulcrum Therapeutics, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Fulcrum Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Fulcrum Therapeutics, Inc. has insufficient data to evaluate this check.

Fulcrum Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Fulcrum Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Fulcrum Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Fulcrum Therapeutics, Inc. has insufficient data to evaluate this check.

Fulcrum Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Fulcrum Therapeutics, Inc. has a price-to-book ratio of 0.92x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Fulcrum Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue